Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.

Abstract

H3K27M-mutant diffuse midline glioma (H3K27M-mt DMG) was a novel entity, which was defined by K27M mutations in H3F3A or HIST1H3B/C in the 2016 WHO updated fourth edition of the central nervous system (CNS) tumor classification. There is an urgent need for effective therapeutic strategies. Anlotinib is a multitarget tyrosine kinase inhibitor, which has not been reported for H3K27M-mt DMG treatment. Here, we firstly reported an adult multifocal H3K27M-mt DMG patient benefiting from anlotinib. This report provides a promising treatment option for H3K27M-mt DMG patients.

• Authors: Qiang Wang, Wenhao Niu, Hao Pan
• Journal: Acta neurochirurgica (Acta Neurochir (Wien)) Vol. 164 Issue 8 Pg. 2063-2066 (08 2022) ISSN: 0942-0940 [Electronic] Austria
• PMID: 34812950 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Chemical References

• Histones
• Indoles
• Quinolines
• anlotinib
• Protein-Tyrosine Kinases
• Receptor, Platelet-Derived Growth Factor alpha

Topics

• Adult
• Brain Neoplasms (drug therapy, genetics)
• Glioma (drug therapy, genetics)
• Histones (genetics)
• Humans
• Indoles (therapeutic use)
• Molecular Targeted Therapy
• Mutation
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Quinolines (therapeutic use)
• Receptor, Platelet-Derived Growth Factor alpha (genetics)